Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aurobindo Injectables Unit Falls Foul Of FDA But Analysts Hopeful

Executive Summary

Aurobindo Pharma Ltd, India’s third-largest drug company by sales, has run into trouble with the US Food and Drug Administration, which has issued nine observations on its key sterile injectables unit in southern India, but analysts are confident there will be only a limited commercial impact.

You may also be interested in...



Signs Of Improving FDA Inspection Outcomes At Indian Sites But Long Road Ahead

Moving up the manufacturing compliance curve is still a work in progress for several Indian firms, but there appear to be some early signs that US FDA inspection outcomes, in general, may have improved.

Sun’s Key Halol Plant Flunks FDA Inspection Again

The US FDA has flagged more issues at Indian firm Sun Pharma’s largest manufacturing plant in Halol but analysts are hoping the infractions are minor and that the Indian facility will get the regulatory green light soon, ending a blacklist on the factory supplying new products to the US.

China Preps For First COVID Vaccine Roll-Outs

Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers. 

Topics

Related Companies

UsernamePublicRestriction

Register

OM013133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel